MORRIS PLAINS, N.J., June 01, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (IMMU) (“Immunomedics” or the “company”), a number one biopharmaceutical company within the area of antibody-drug conjugates (ADC), today announced that the company plans to initiate a section 2 pivotal TROPHY U-01 examine of sacituzumab govitecan, the company’s lead investigational ADC, as a single agent in patients with in the community advanced or metastatic urothelial cancer (mUC) who have relapsed after a platinum-primarily based regimen and/or immune checkpoint inhibitor (CPI) remedy.
“Urothelial cancer sufferers who have relapsed after, or are refractory to platinum chemotherapy and the lately accredited CPI remedies, have a big unmet need with few attainable treatment alternatives,” remarked Dr. Rob Iannone, Head of R&D and Chief clinical Officer of Immunomedics. “we are completely satisfied with the FDA suggestions on analyze design and protocol development, which is aligned with the enterprise’s aim to bring this talents vital treatment alternative to patients expeditiously.”
The phase 2 pivotal examine, which is anticipated to be activated next week, will be a single arm, foreign, multicenter study so one can join about 100 mUC patients who have bought prior platinum-primarily based and CPI treatment. The primary endpoint might be ordinary response price, with length of response, progression-free survival, and ordinary survival serving as secondary endpoints. Response assessments can be in response to RECIST 1.1 and all patients might be centrally reviewed. moreover, the study will additionally join an extra and separate cohort of patients who're cisplatin ineligible and have received prior CPI treatment to consider defense and efficacy in an previous medication setting.
About Sacituzumab GovitecanSacituzumab govitecan, our most superior product candidate, is a novel, first-in-class antibody-drug conjugate (ADC). it's at the moment below assessment via the U.S. food and Drug Administration for accelerated approval as a medicine of sufferers with metastatic triple-poor breast cancer who previously received at least two prior remedies for metastatic disorder. If authorized, sacituzumab govitecan often is the first and best ADC permitted for the treatment of metastatic triple poor breast cancer.
About ImmunomedicsImmunomedics is a clinical-stage biopharmaceutical business constructing monoclonal antibody-based mostly items for the centered treatment of melanoma and other critical illnesses. Immunomedics’ corporate goal is to become a totally-built-in biopharmaceutical enterprise and a pacesetter within the box of antibody-drug conjugates. For additional info on the enterprise, please visit its site at https://immunomedics.com/. The suggestions on its web site does not, besides the fact that children, kind a part of this press liberate.
Cautionary word involving ahead-searching statementsThis liberate, in addition to old counsel, may additionally contain forward-searching statements made pursuant to the deepest Securities Litigation Reform Act of 1995. Such statements, including statements involving medical trials (including the funding therefor, anticipated patient enrollment, trial consequences, timing or linked fees), regulatory purposes and connected timelines, together with the submitting and approval timelines for BLAs and BLA dietary supplements, out-licensing arrangements, forecasts of future working effects, expertise collaborations, capital elevating actions, and the timing for bringing any product candidate to market, contain huge dangers and uncertainties and genuine consequences might fluctuate materially from these expressed or implied herein. components that may trigger such alterations consist of, but are not restricted to, the company’s dependence on enterprise collaborations or availability of required financing from capital markets, or other sources on applicable terms, if at all, with the intention to extra enhance our products and finance our operations, new product development (including scientific trials influence and regulatory necessities/moves), the possibility that we or any of our collaborators could be unable to at ease regulatory approval of and market our drug candidates, dangers associated with the result of pending litigation and competitive hazards to marketed items, and the business’s ability to repay its outstanding indebtedness, if and when required, as well as the dangers discussed within the enterprise’s filings with the Securities and change commission. The enterprise is not below any responsibility, and the enterprise expressly disclaims any duty, to update or alter any ahead-searching statements, whether on account of new counsel, future activities or in any other case.
Editor's be aware: in the hunt for Alpha is proud to welcome Jeff Hetmansperger as a brand new contributor. it's convenient to turn into a in quest of Alpha contributor and earn money to your ideal investment ideas. energetic contributors additionally get free access to SA seasoned. click here to find out more »
BiolineRx (NASDAQ:BLRX) is a clinical-stage bio-pharmaceutical enterprise working primarily as company development entity seeking to determine, in-license, and improve promising drug candidates generated via research corporations, universities, and small biotech startamericain Israel and globally. These drug candidates are put via a complete screening manner to make sure their technical and scientific feasibility, IP protection, and their business knowledge. through this technique, the enterprise has developed a broad and wealthy pipeline in different therapeutic areas, primarily in oncology and immunology.
I trust BiolineRx is at a big inflection point and its valuation is set to change in a massive approach in 2018. this text will focus on the the reason why i am so confident and bullish concerning the present and the future of this company. under are one of the crucial the explanation why I accept as true with BiloineRx is at present grossly undervalued:
For a corporation with a market cap of little over $100M, BioLineRx has essential collaborations with main pharma companies like Novartis (NYSE:NVS), Merck (NYSE:MRK), and Genentech/Roche (OTCQX:RHHBY). The strategic collaboration with Novartis is for the co-building of selected Israeli sourced novel drug candidates. With Merck, the enterprise is operating a section 2 look at in pancreatic melanoma the use of the combination of its lead compound BL8040, and Merck's KEYTRUDA. throughout the collaboration settlement with Genentech, the business is investigating the aggregate of BL8040 and Genentech's atezolizumab in distinctive strong tumor signals and AML.
The Novartis collaboration became introduced on December 16, 2014. during the multi-year partnership, Novartis will have entry to the optimum drug candidates recognized through BiolineRx in the enviornment of immunology. Novartis invested an initial $10 million by means of acquiring 5 million BLRX shares in a personal transaction at $2.00 a share.
as soon as a undertaking is chosen, Novartis pay BioLineRx an option fee of $5 million and fund half the final construction expenses in the sort of an extra equity funding within the business. An instance of this collaboration is the settlement announced on September 23, 2016, whereby BioLineRx signed an exclusive worldwide settlement to in-license liver candidate BL-1220 to deal with end-stage liver sickness and stipulations resulting in liver failure akin to NASH.
related to this deal, Philip Serlin, BiolineRx CEO commented:
“In August this 12 months, we in-licensed the first compound beneath our multi-12 months strategic partnership with Novartis, a novel drug candidate for controlling liver fibrosis via modulation of the immune system.”
“both of those initiatives healthy our strategic center of attention on the immunology house. We continue to work intently with Novartis to determine cutting-area, novel healing procedures and we expect to bring extra promising tasks to the collaboration with the aid of the conclusion of the 12 months," he introduced.
i'll deliver more colour on the Novartis, Genentech, and Merck collaborations later in this article.January 2018 A Busy Month For BLRX
January 2018 turned into the busiest month in business's history related to participation in conferences (Biotech show off and JPM health conference) and proposing medical records at ASCO Gastrointestinal Cancers Symposium and ASCO_SITC Immuno-Oncology Symposium. These 4 conferences have been held in San Francisco, CA.
right here is a summary for essentially the most notable scientific records presented through BiolineRX in January 2018:
At ASCO Gastro, the enterprise presented partial effects from the monotherapy component of BL-8040's part 2a fight study (with Merck's KEYTRUDA) showing a major infiltration of T cells into the tumor in patients with metastatic pancreatic cancer. The consequences showed as much as a 15-fold enhance in CD3+ T cells, and up to a 2-fold enhance in CD8+ T cells, in the tumor micro-environment (TME) of 43% of the patients, after 5 days of BL-8040 monotherapy. The partial outcomes showed that BL-8040 became secure and smartly-tolerated.
Lead investigator, world-well-known oncology knowledgeable Dr. Manuel Hidalgo commented:
"this is the first time we see outcomes of BL-8040 in pancreatic melanoma patients. The effects of the monotherapy part of the fight trial are extraordinarily encouraging as they ascertain the mechanism of motion of BL-8040 in this complex-to-treat patient population, leading to T-cellphone infiltration into the tumor after simplest 5 days of monotherapy with BL-8040. These effects help the rationale for combining BL-8040 with checkpoint inhibitors, and i am eager for the topline effects of the fight look at anticipated later this year."
Philip Serlin, Chief government Officer of BioLineRx brought,
"The results display that BL-8040 induces robust infiltration of anti-tumor T cells into liver metastases in nearly half of the pancreatic cancer sufferers who underwent a biopsy, simply reworking these tumors from immunologically 'cold' to 'hot', which is viewed as key in the goal of improving the responsiveness of patients with pancreatic melanoma to front-line immunotherapy."
T-cellphone infiltration might be a key to enrich response to therapy. this can flip the tumor from bloodless to sizzling, and hence render it delicate to remedy.
here slide is BiolineRx depiction on how BL-8040 is envisioned to work within the tumor micro-ambiance (TME), which changed into validated with this data, and why Merck and Genentech are doing clinical trials in mixture with their blockbuster immunotherapy agents KEYTRDUDA and Tecentriq respectively (from December 2017 company presentation):
The enterprise introduced the identical records at ASCO-SITC the following week.
The subsequent BL-8040 presentation entitled, "CXCR4 antagonist (BL-8040) to enhance antitumor consequences by way of expanding tumor infiltration of antigen-certain effector T-cells. (abstract 73)," turned into delivered at ASCO-SITC Immuno-Oncology January 25 -27, 2018.
The records further validated the MOA, depicted in the slide above, displaying remedy with BL-8040, in aggregate with a melanoma vaccine that primes the immune device towards the tumor, vastly improved the anti-tumor response in comparison to either agent administered by myself. The outcomes confirmed that BL-8040 significantly raises the abundance of tumor-certain T-cells within the TME.
Lead investigator, oncology professor Dr. Samir Khleif, had this to say about these outcomes:
"i'm highly inspired by way of the statistics generated in this preclinical study, which extra demonstrates the therapeutic capabilities of BL-8040. The effects provide extra proof that BL-8040 promotes the infiltration of cytotoxic T-cells into tumors, which is seen as a key aim to enrich responsiveness to checkpoint remedy. I appear ahead to seeing the consequences from the medical reports by which BL-8040 is being combined with checkpoint blockade (KEYTRUDA and Tecentriq)."
CEO Philip Serlin added,
"we've shown in a lot of preclinical and clinical reports that BL-8040 has quite a few anti-tumor outcomes, including direct and indirect outcomes, influencing T-phone vicinity and undertaking as well as tumor mobile survival. The outcomes of the existing study indicate that BL-8040 enhances anti-tumor immune response via expanding the variety of anti-tumor T-cells within the TME. These consequences also indicate that BL-8040, a CXCR4 antagonist, is a promising immune-modulatory agent with powerful anti-tumor effects, and we remain not off course with our eight ongoing medical trials for this product in numerous signs, each in blood cancers as well as in solid tumors."
The third facts presentation in January involved new oncology asset AGI-134. The presentation entitled: "Intratumoral administration of the alpha-Gal glycolipid AGI-134 to result in tumor regression in a mouse mannequin of melanoma. (summary 68)." become introduced at ASCO-SITC Immuno-Oncology January 25 - 27, 2018.
These effects have been nothing wanting outstanding. records from two mouse melanoma fashions confirmed intratumorally injected AGI-134 brought about complete tumor regression in 50% and sixty seven% of mice, respectively. treatment with AGI-134 additionally showed a positive impact on survival compared to control.
CEO Philip Serlin commented:
"previous reviews have established that intratumoral administration of AGI-134 induces a systemic anti-tumor response that protects mice from the building of distant tumors. These new reports now reveal direct regression of established fundamental tumors after injection with AGI-134, and that this regression is associated with activation of the innate immune equipment."
"These compelling pre-medical data guide investigating this method in a part 1/2a study, and we're excited and on track to commence a primary-in-man analyze with this promising novel oncology asset in sufferers with solid tumors within the first half of 2018."
The information introduced at ASCO_SITC validates AGI-134's MOA which, after injection right into a tumor, generates a pro-inflammatory tumor microenvironment that pulls and prompts other immune cells, subsequently resulting in adaptive anti-tumor immunity, as a consequence killing the injected as neatly as the far-off metastasized tumors. The slide beneath suggests the conceptual AGI-134 MOA:
Melanoma is essentially the most serious category of dermis melanoma because it can spread or metastasize to other tissues and organs within the body. Metastatic melanoma regularly spreads to the tissue beneath the skin, lymph nodes, lungs, liver and brain. contemporary advances in treatment have tremendously prolonged survival in some patients with metastatic melanoma. youngsters, new treatments are nonetheless urgently crucial to help more sufferers control their disease. it is envisioned that AGI-134 may also be advantageous as a monotherapy and in combination with permitted immunotherapy drugs.extra On BL-8040
BL8040, as a powerful CXCR4 antagonist, has the capabilities to goal and kill numerous solid tumor melanoma cells as well as hematological melanoma cells. BL8040 has shown to induce mobilization of malignant cells into the peripheral blood from their hiding locations like the bone marrow, which gives coverage from chemotherapeutic brokers. previous clinical studies have proven that BL8040 is effective, each alone and in mixture with different cancer medicine, in cutting back bone marrow metastasis of lymphoma cells and stimulating apoptosis, or lymphoma mobile death.
BL-8040 medical records shared through the enterprise on December four, 2017, showed that BL-8040 in its phase 2a trial for the remedy of relapsed or refractory acute myeloid leukemia in aggregate with excessive-Dose Cytarabine (HiDAC), significantly more suitable typical survival, compared with old records of HiDAC mono-remedy. The mixture of BL-8040 with HiDAC become well tolerated displaying a response expense of 38%. Median average survival become 11.1 months, the estimated one-yr survival price become 37.5% and the estimated two-yr survival expense become 28.5%. This compares favorably to ancient facts for sufferers treated with HiDAC monotherapy displaying overall survival of handiest 6.1 months. moreover, the subset of sufferers exhibiting a response showed extended ordinary survival, with estimated one-12 months and two-yr survival prices of 60%.
After these results had been out, Oppenheimer reiterated its Outperform rating at $3/share fee goal on the stock. Analyst Mark Breidenbach commented, "We trust BL-8040 might generate adequate earnings revenues as a stem cell mobilizer to look the company cash flow wonderful by 2021. additionally, the drug may additionally prove to be an exceptional chemo-sensitizer for sufferers with leukemia, and the next 12-18 months are replete with catalysts, together with an meantime readout from a randomized AML examine."
also on December four, 2017, Maxim neighborhood set a $three.00 goal fee on BiolineRx and gave the company a buy score in a research report.
Following the December 21, 2017 announcement that the company initiated its section 3 medical trial, GENESIS, assessing BL-8040 for the mobilization of hematopoietic stem cells for autologous transplantation in diverse myeloma patients, HC Wainwright set a $4.00 target cost on BiolineRx on a analysis note issued on December 25, 2017. The brokerage currently has a buy ranking on the inventory.
GENESIS will examine the mixture of BL-8040 and granulocyte colony-stimulating aspect (G-CSF) to placebo plus G-CSF in about a hundred and eighty topics. The fundamental endpoint will be the percentage of sufferers who mobilize a prescribed minimum number of CD34+ cells with up the two apheresis periods after a single administration of BL-8040 and G-CSF.
a different essential recent development the business announced on October 18, 2017, the initiation of a mixture trial of BL-8040 and atezolizumab (Genentech's Tecentriq) in patients with gastric cancers. this is a part of the initiative for the building of novel cancer immunotherapy combinations between the business's BL-8040 powerful CXCR4 antagonist and Genentech's multi-billion dollar anti-PDL1 melanoma immunotherapy agent addressing a number of strong tumors including pancreatic, gastric and non-small cell lung melanoma.
right here slide depicts the medical plan to execute this essential clinical trial:
also with Tecentriq, the company announced on September 26, 2017, the initiation of section 1b/2 trial, named fight, assessing the aggregate of BL-8040 and atezolizumab for the preservation medicine of sufferers with intermediate and high-chance acute myeloid leukemia who have accomplished a complete response following induction and consolidation remedy.
The trial will sign up as much as 60 patients. The fundamental endpoint is relapse-free survival. The effect of the aggregate remedy on minimal residual sickness, multiple immunological parameters and advantage biomarkers will also be evaluated.
The section 2 partial consequences for the combat scientific trials stated at ASCO Gastro 2018, and discussed above, are for the BL-8040 monotherapy element of the reviews earlier than the introduction of KEYTRUDA (factor 5 in right here slide). This step is essential to show pancreatic cancer cells by using priming the micro-tumor atmosphere in order that KEYTRUDA can go to work and kill the tumors extra without difficulty:
Full part 2 statistics for these trials can be pronounced in 2H 2018.greater On AGI-134
BioLineRx (BLRX) introduced on March 23, 2017, the acquisition of Agalimmune Ltd., a private UK-based mostly enterprise with an ingenious, anti-melanoma immunotherapy platform having AGI-134 as its lead drug candidate. BioLineRx reportedly paid $6M upfront, with $3M in cash and the the rest in BLRX shares.
within the acquisition announcement, BioLineRx CEO Serlin commented:
"Agalimmune's lead asset, AGI-134, harnesses naturally happening, pre-latest antibodies to elicit a tumor-specific immune response it really is wonderful to the treated individual and gives a frequent, small-molecule method to customized immunotherapy. we're enthusiastic to include into our pipeline this promising close-scientific asset, which noticeably strengthens our place within the immuno-oncology house."
In layman's phrases, Agalimmune's technology works by harnessing the physique's personal immune gadget to kill solid tumors. The drug is injected right into a goal tumor, and thru a series of movements, it kills the local tumor. once particles from the killed tumor enters the blood circulate, the body's immune gadget generates and programs T-cells, in keeping with the chemical structure of the killed tumor, and attacks and kills all of the other tumors that resulted via metastasis. This consequences in a personalised remedy, potentially leading to stronger responses over other existing strong-tumor technologies. The mechanism of motion of AGI-134 reminds me of Idera's (IDRA) lead drug candidate for strong tumors, IMO-2125, the use of a wholly distinctive method. With a tremendously smaller pipeline, Idera's market cap become 4 instances better than BiolineRX earlier than the January 22, 2018 announcement that it had merger with BioCryst Pharma. i will be able to talk about the disconnect between BilioneRx low valuation and its huge upside competencies.
AGI-134, as a small molecule that can generate systemic T mobile responses towards the patient's own neoantigens in situ and with a benign safety profile, it can be a fantastic candidate to use in aggregate with immunotherapies similar to checkpoint inhibitors.
AGI-134 has efficiently completed numerous pre-medical studies. In these stories, AGI-134 demonstrated positive destruction of fundamental and secondary tumors and supplied strong insurance policy in opposition t the formation of new tumors in melanoma models with a single dose most effective. The drug has also demonstrated a synergistic impact when combined with checkpoint inhibitors in extra pre-clinical reports. this is another reason BLRX's management is so bullish in regards to the drug's prospects when you consider that it would offer the chance to increase the price and duration of responses in distinct cancer forms with the aid of working at the side of checkpoint inhibitors.
as a result of its novel mechanism of action, AGI-134 is a opening new frontier within the fight towards melanoma the place presently it be the most effective player. Being first, and being successful in oncology is rewarded accordingly in due time.Pipeline
The December 2017 company Presentation shows the popularity of the latest pipeline
As can also be seen in the slide above, besides oncology and immunotherapy collaborations with Genentech and Merck, the business is working with a few drug candidates within the enviornment of immunology, essentially with Novartis. The slide additionally shows that that its BL-5010 dermatological drug has reached business stage. On April 4, 2016, the business announced that its partner Omega Pharma (now a part of Perrigo) has received CE Mark approval for BL5010 as a novel OTC medication for the nonsurgical removing of dermis lesions. The business expects to document significant revenues as the advertising plans for BL5010 are being done.most important Upcoming medical Milestones
right here slide suggests principal milestones that traders may still expect in 2018. observe that the shows proven on table 1 aren't protected within the slide as a result of they are simplest meantime facts, however even so very essential within the manner of building the price of BL-8040 and AGI-134 as competencies blockbuster drug candidates addressing a big range of oncology indications.
investors will notice in dismay that insiders don't personal any company shares. The motive is awfully standard, they aren't allowed to do it as a result of BiloineRx is primarily a "business building firm" working three hundred and sixty five days a year on small to colossal offers to expand the pipeline, to enter into gigantic pharma collaborations, acquire or dispose property, etc. buying shares with the insider advantage of a huge effective building would constitute "Insider trading." The corporate Governance files detail these guidelines to your assistanceInstitutional possession
For a inventory buying and selling close to $1/share, BiolineRx has very robust institutional aid with a current 40% ownership (up from 15% two quarters in the past). Bvf Inc, the biggest holder, extended its stake in Biolinerx Ltd (BLRX) through forty eight.fifty five% from 17.5M to 26M shares in accordance with its latest 2017Q3 regulatory filing with the SEC. Novartis owns 5.4M shares of BLRX inventory. Deutsche bank Ag, Morgan Stanley, Renaissance technologies, and other gigantic traders were including in fresh quarters. A contemporary Seekingalpha blog publish by contributor Hawkinvest entitled: "BioLine RX: This $1 Biotech stock offers a superb possibility To Reward Ratio And Upside Catalysts For 2018," gives a greater wide dialogue of this, and different crucial themes involving this security.hazards and uncertainties
as with every biotech in the medical-construction stage, there are a couple of expertise hazards that should still be considered:
The business has been making huge growth due to the fact Philip Serlin changed into named CEO of BiolineRx in August 2016. This progress accelerated in 2017, and the momentum is carrying into 2018 positioning the company for a considerable raise in valuation. Any biotech having pronounced the robust medical consequences of the ultimate two weeks on properly of what turned into finished in 2017 could have doubled or tripled in valuation. Many latest BLRX owners are disappointed in regards to the stock performance to date, and many might have left early in search for greener pastures. but I consider there are causes for it, and as soon as the sentiment adjustments, BLRX will attain new highs. listed here are some of these explanations:
With the company making colossal growth on its high-abilities pipeline, having a powerful stability sheet, and with the subsequent 12-18 months replete with potentially potent catalysts, the inventory will no longer remain this undervalued perpetually. Analyst concur with this statement as their rate ambitions of $3 to $four/share suggests very giant upside competencies. The expertise draw back possibility is low considering that the company is buying and selling simplest 30c above money value.
for my part, I do not know of any sub-$5 biotech and sub $500M market cap that offer a more diverse and promising pipeline portfolio than BioLineRx offers. I've mentioned Idera (NASDAQ: IDRA) as an instance, however i will also feel of AVEO Pharma (NASDAQ: AVEO), Infinity Pharma (NASDAQ: INFI) and a lot of different biotechs having a fraction of BiolineRX's pipeline with market caps three - 5 instances higher. additionally, there are no sub-$500M market cap biotechs which have partnerships and collaboration with three of the biggest pharma companies on this planet.
The relaxation of 2018 is also loaded with foremost catalysts like topline part 2 pancreatic cancer with MRK's KEYTRUDA, effects of BL-8040 trials with Genentech's Tecentriq, a few medical outcomes for liquid cancers, initiation of AGI-134 in-human trials, and advancing several immunology courses with accomplice Novartis (NASH, diabetes, ophthalmology, and so forth.).
The massive talents packed with BiolineRX is being mentioned via primary investors like BVF partners having invested just about $30M bucks in BioLineRx after an instantaneous $9.6 million investment at $1.13 per unit, for standard shares and warrants with 4-yr phrases. because warrants are priced at $2 and $4/share means that this universal funding enterprise believes this inventory will eventually trade above $2 and even $4 per share.
BLRX, as any stock available in the market, and specially since it can be a very volatile biotech stock, it may also be very dangerous regardless of its advantage. investors may still all the time assessment in element the entire dangers and uncertainties as listed in the business's filings with the SEC.
Disclosure: i am/we're long BLRX.
I wrote this text myself, and it expresses my own opinions. i'm not receiving compensation for it (apart from from in search of Alpha). I haven't any business relationship with any company whose inventory is mentioned listed here.
Editor's word: this article covers one or extra stocks trading at under $1 per share and/or with less than a $one hundred million market cap. Please be aware about the hazards linked to these shares.
PRINCETON, N.J.--(company WIRE)--Bristol-Myers Squibb enterprise (NYSE:BMY) these days introduced that the Committee for Medicinal products for Human Use (CHMP) of the european medicines company (EMA) has adopted a favorable opinion recommending that Opdivo (nivolumab), a PD-1 immune checkpoint inhibitor, be granted acclaim for use in both first-line and prior to now treated patients with advanced (unresectable or metastatic) melanoma. here is the first superb opinion given by the CHMP for a PD-1 immune checkpoint inhibitor, and it'll now be reviewed by the eu commission, which has the authority to approve drugs for the european Union (european).
The EMA granted Bristol-Myers Squibb accelerated assessment of Opdivo in response to existing laws that fulfills its guidance about “medicinal items of fundamental hobby from the aspect of view of public fitness and in selected from the view element of therapeutic innovation.”
“we are blissful with nowadays’s CHMP superb opinion, as it is a step nearer to us bringing this critical medication for these superior melanoma sufferers in Europe in need of new alternate options,” spoke of Michael Giordano, senior vice chairman, Head of building, Oncology. “Our imaginative and prescient is to radically change how we approach cancer – from clinical practice to improved affected person effects. We continue to extend the breadth and depth of our immuno-oncology portfolio across the continuum of melanoma and numerous other cancers, to give more sufferers with the knowledge possibility for lengthy-time period survival.”
superb Opinion in line with CheckMate -066, -037
The CHMP advantageous opinion is in response to facts from two part III stories (CheckMate -066 and -037), demonstrating the efficacy and safety of Opdivo in advanced melanoma sufferers with critical unmet needs. CheckMate -066, a part III randomized double-blind analyze, comparing Opdivo to the chemotherapy dacarbazine (DTIC) in patients with medication-naïve superior melanoma, is the primary phase III trial of an investigational PD-1 immune checkpoint inhibitor to exhibit an average survival improvement in advanced melanoma, as well as a stronger purpose response fee. A 2nd study, CheckMate -037, is a part III randomized, controlled open-label look at of Opdivo versus investigator’s alternative chemotherapy in sufferers with advanced melanoma who were previously handled with Yervoy (ipilimumab), which showed development in objective response rates. These records are supported by means of a phase Ib look at (examine -003) in relapsed advanced or metastatic melanoma, which demonstrated the primary characterization of Opdivo improvement/possibility in superior melanoma. There was consistent Opdivo dosing of 3 mg/kg each two weeks across all three trials.
Bristol-Myers Squibb has a vast, global building software to examine Opdivo in diverse tumor forms such as greater than 50 trials – as monotherapy or in aggregate with different cures – wherein more than 7,000 patients had been enrolled global.
Opdivo became the primary PD-1 immune checkpoint inhibitor to acquire regulatory approval anywhere in the world on July four, 2014 when Ono Pharmaceutical Co. announced that it got manufacturing and advertising approval in Japan for the remedy of sufferers with unresectable melanoma. within the U.S., the U.S. food and Drug Administration (FDA) granted its first popularity of Opdivo for the medication of patients with unresectable or metastatic melanoma and sickness development following Yervoy (ipilimumab) and, if BRAF V600 mutation tremendous, a BRAF inhibitor. On March 5, 2015, Opdivo lately obtained its 2nd FDA popularity of the medicine of sufferers with metastatic squamous non-small phone lung melanoma (NSCLC) with progression on or after platinum-primarily based chemotherapy.
About advanced Melanoma
Melanoma is a sort of skin cancer characterised through the uncontrolled increase of pigment-producing cells (melanocytes) found within the epidermis. Metastatic melanoma is the deadliest sort of the disease, and happens when cancer spreads beyond the surface of the epidermis to the other organs, such as the lymph nodes, lungs, mind or other areas of the body. The incidence of melanoma has been expanding for at least 30 years. In 2012, an estimated 232,130 melanoma cases were clinically determined globally. Melanoma is commonly curable when treated in its early levels. however, in its late ranges, the general survival rate has traditionally been simply six months with a one-12 months mortality fee of 75%, making it one of the vital aggressive sorts of melanoma.
Immuno-Oncology at Bristol-Myers Squibb
surgery, radiation, cytotoxic or targeted treatment options have represented the mainstay of cancer medication over the last several decades, but lengthy-time period survival and a good excellent of life have remained elusive for many sufferers with advanced ailment.
To address this unmet medical want, Bristol-Myers Squibb is main research in an resourceful box of melanoma analysis and treatment called immuno-oncology, which contains agents whose primary mechanism is to work without delay with the physique’s immune system to fight cancer. The enterprise is exploring a lot of compounds and immunotherapeutic procedures for patients with various kinds of cancer, together with learning the skills of mixing immuno-oncology agents that target different and complementary pathways in the medication of cancer.
Bristol-Myers Squibb is dedicated to advancing the science of immuno-oncology, with the aim of changing survival expectations and the manner sufferers are living with melanoma.
concerning the Bristol-Myers Squibb and Ono Pharmaceutical Collaboration
In 2011, via a collaboration agreement with Ono Pharmaceutical, Bristol-Myers Squibb expanded its territorial rights to develop and commercialize Opdivo globally apart from in Japan, South Korea and Taiwan, where Ono had retained all rights to the compound on the time. On July 23, 2014, Bristol-Myers Squibb and Ono Pharmaceutical extra improved the groups’ strategic collaboration agreement to jointly advance and commercialize distinct immunotherapies – as single agents and mixture regimens – for sufferers with melanoma in Japan, South Korea and Taiwan.
important security assistance
Immune-Mediated Nephritis and Renal Dysfunction
Immune-Mediated Hypothyroidism and Hyperthyroidism
other Immune-Mediated adversarial Reactions
critical hostile Reactions
usual antagonistic Reactions
Please see US Full Prescribing guidance for OPDIVO.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global pharmaceutical business whose mission is to find, boost and deliver creative drug treatments that support patients be triumphant over critical illnesses. For greater guidance about Bristol-Myers Squibb, visit www.bms.com, or observe us on Twitter at http://twitter.com/bmsnews.
Bristol-Myers Squibb forward-searching statement
This press release contains "ahead-searching statements" as that time period is defined in the private Securities Litigation Reform Act of 1995 concerning the analysis, construction and commercialization of pharmaceutical items. Such ahead-looking statements are according to existing expectations and involve inherent risks and uncertainties, including components that could delay, divert or change any of them, and could cause specific results and outcomes to vary materially from existing expectations. No ahead-looking remark will also be guaranteed. among different dangers, there can be no be sure that Opdivo will acquire regulatory approval within the European Union or, if authorised, that it is going to become a commercially a hit product. forward-searching statements during this press release should be evaluated along with the numerous uncertainties that affect Bristol-Myers Squibb's business, especially those recognized in the cautionary elements discussion in Bristol-Myers Squibb's Annual report on form 10-ok for the 12 months ended December 31, 2014 in our Quarterly studies on form 10-Q and our latest experiences on form eight-ok. Bristol-Myers Squibb undertakes no duty to publicly replace any ahead-searching commentary, whether on account of new assistance, future events or in any other case.
While it is hard errand to pick solid certification questions/answers assets regarding review, reputation and validity since individuals get sham because of picking incorrectly benefit. Killexams.com ensure to serve its customers best to its assets as for exam dumps update and validity. The greater part of other's sham report objection customers come to us for the brain dumps and pass their exams cheerfully and effortlessly. We never bargain on our review, reputation and quality because killexams review, killexams reputation and killexams customer certainty is imperative to us. Extraordinarily we deal with killexams.com review, killexams.com reputation, killexams.com sham report grievance, killexams.com trust, killexams.com validity, killexams.com report and killexams.com scam. On the off chance that you see any false report posted by our rivals with the name killexams sham report grievance web, killexams.com sham report, killexams.com scam, killexams.com protestation or something like this, simply remember there are constantly terrible individuals harming reputation of good administrations because of their advantages. There are a great many fulfilled clients that pass their exams utilizing killexams.com brain dumps, killexams PDF questions, killexams rehearse questions, killexams exam simulator. Visit Killexams.com, our example questions and test brain dumps, our exam simulator and you will realize that killexams.com is the best brain dumps site.
Killexams 9A0-046 test prep | Killexams S90-05A entrance exam | Killexams A00-280 study guide | Killexams 1V0-621 practice questions | Killexams 310-105 dump | Killexams EE0-071 free test online | Killexams CGFM practice test | Killexams HP0-651 online test | Killexams 000-900 test questions | Killexams PARCC sample test | Killexams 000-905 bootcamp | Killexams 642-035 Practice test | Killexams NS0-504 test questions and answers | Killexams FM0-302 braindumps | Killexams LOT-924 boot camp | Killexams 250-503 flashcards | Killexams 000-218 pdf download | Killexams 1Y0-301 free pdf | Killexams CAT-241 Practice Test | Killexams HP0-058 free pdf |
Just study these CheckPoint 156-915-1 Questions and Pass the real test
killexams.Com pinnacle price 156-915-1 Exam Testing Tool is extraordinarily encouraging for our customers for the exam readiness. Immensely critical highlights, factors and definitions are featured in thoughts dumps pdf. Social event the information in a single location is a authentic help and reasons you get prepared for the IT accreditation examination inside a quick timeframe traverse. The 156-915-1 confirmation gives key focuses. The killexams.Com pass4sure dumps keeps the vital highlights or ideas of
At killexams.Com, we provide absolutely studied CheckPoint 156-915-1 getting ready sources which are the pleasant to clean 156-915-1 take a look at, and to get asserted by way of CheckPoint. It is a fine choice to animate your employment as a specialist in the Information Technology industry. We are glad with our reputation of supporting human beings clean the 156-915-1 take a look at of their first undertakings. Our thriving fees inside the beyond two years have been absolutely extraordinary, because of our cheery clients who are currently prepared to result in their livelihoods in the maximum optimized plan of assault. Killexams.Com is the primary choice among IT specialists, in particular those who're making plans to climb the movement ranges faster in their individual affiliations. CheckPoint is the commercial enterprise pioneer in information development, and getting avowed by them is a assured way to cope with win with IT jobs. We empower you to do efficaciously that with our notable CheckPoint 156-915-1 getting ready substances.
CheckPoint 156-915-1 is omnipresent all around the international, and the business and programming publications of action gave by means of them are being gotten a manage on by way of every one of the associations. They have helped in using an in depth quantity of associations on the with out question shot method for accomplishment. Expansive mastering of CheckPoint matters are seen as a basic ability, and the experts affirmed through them are uncommonly seemed in all affiliations.
We provide sincere to goodness 156-915-1 pdf examination request and solutions braindumps in two plans. Download PDF and Practice Tests. Pass CheckPoint 156-915-1 e book Exam fast and viably. The 156-915-1 syllabus PDF kind is to be had for inspecting and printing. You can print steadily and exercise usually. Our bypass price is high to ninety eight.9% and the similarity fee among our 156-915-1 syllabus keep in mind manage and certifiable examination is ninety% in mild of our seven-yr instructing basis. Do you require achievements inside the 156-915-1 examination in just a unmarried undertaking? I am at the existing time analyzing for the CheckPoint 156-915-1 syllabus examination.
Cause the principle factor that is in any capacity critical here is passing the CheckPoint 156-915-1 exam. Cause all that you require is a excessive rating of CheckPoint 156-915-1 exam. The best a solitary element you need to do is downloading Examcollection 156-915-1 examination don't forget coordinates now. We wont can help you down with our unrestricted guarantee. The experts in like manner keep pace with the maximum best in elegance examination to give maximum of invigorated substances. One 12 months loose access to have the potential to them via the date of procurement. Every candidate may additionally endure the cost of the CheckPoint examination dumps thru killexams.Com requiring little to no effort. Habitually there is a markdown for absolutely everyone all.
Inside seeing the bona fide exam substance of the mind dumps at killexams.Com you can with out a whole lot of an amplify broaden your declare to repute. For the IT professionals, it's miles basic to enhance their capacities as showed with the aid of their work need. We make it fundamental for our customers to hold certification examination with the help of killexams.Com affirmed and sincere to goodness exam cloth. For an awesome destiny in its area, our mind dumps are the first-rate decision.
A first-rate dumps growing is a basic segment that makes it trustworthy a good way to take CheckPoint accreditations. In any case, CheckPoint braindumps PDF offers settlement for candidates. The IT declaration is a important tough endeavor if one doesnt discover true course as apparent resource fabric. Thus, we've got proper and invigorated substance for the arranging of confirmation examination.
It is essential to acquire to the manual material in case one wishes in the direction of shop time. As you require packs of time to look for revived and true exam material for taking the IT accreditation examination. If you find that at one region, what may be higher than this? Its really killexams.Com that has what you require. You can save time and keep a strategic distance from trouble in case you purchase Adobe IT accreditation from our website.
You need to get the maximum revived CheckPoint 156-915-1 Braindumps with the precise answers, which can be set up by way of killexams.Com professionals, empowering the likelihood to apprehend finding out approximately their 156-915-1 affirmation course inside the first-class, you wont locate 156-915-1 outcomes of such satisfactory wherever within the marketplace. Our CheckPoint 156-915-1 Practice Dumps are given to applicants at acting 100% in their exam. Our CheckPoint 156-915-1 test dumps are modern day inside the market, permitting you to prepare on your 156-915-1 examination in the proper manner.
If you are possessed with viably finishing the CheckPoint 156-915-1 Certification to start obtaining? Killexams.Com has riding area made CheckPoint exam has a tendency to so as to promise you pass this 156-915-1 examination! Killexams.Com passes on you the maximum correct, gift and cutting-edge revived 156-915-1 Certification examination questions and open with a 100% authentic assure ensure. There are severa institutions that provide 156-915-1 thoughts dumps but the ones are not genuine and cutting-edge ones. Course of motion with killexams.Com 156-915-1 new request is a most perfect way to deal with bypass this certification examination in primary manner.
Killexams.Com Huge Discount Coupons and Promo Codes are as below;
WC2017 : 60% Discount Coupon for all exams on website
PROF17 : 10% Discount Coupon for Orders extra than $sixty nine
DEAL17 : 15% Discount Coupon for Orders extra than $ninety nine
DECSPECIAL : 10% Special Discount Coupon for All Orders
We are usually specially mindful that an imperative difficulty within the IT business is that there is a nonattendance of enormous well worth don't forget materials. Our examination preparation material gives all of you that you should take an affirmation examination. Our CheckPoint 156-915-1 Exam will give you examination request with affirmed answers that reflect the real exam. These request and answers provide you with the revel in of taking the honest to goodness test. High bore and impetus for the 156-915-1 Exam. One hundred% confirmation to pass your CheckPoint 156-915-1 exam and get your CheckPoint attestation. We at killexams.Com are made plans to empower you to clean your 156-915-1 accreditation check with excessive ratings. The chances of you fail to clean your 156-915-1 test, in the wake of encountering our sweeping exam dumps are for all intents and functions nothing.
Killexams CRFA study guide | Killexams 000-870 study guide | Killexams C2180-529 essay questions | Killexams HP2-T23 cram | Killexams 1T6-530 boot camp | Killexams A6040-752 brain dumps | Killexams N10-006 braindumps | Killexams 1Z0-573 practice questions | Killexams QQ0-400 test questions | Killexams 9L0-418 online test | Killexams 000-858 cbt | Killexams 00M-246 test questions and answers | Killexams CAT-280 Practice test | Killexams ST0-47W test answers | Killexams 1D0-437 dump | Killexams A2090-544 practice questions | Killexams C9020-461 bootcamp | Killexams 70-497 free test online | Killexams 310-813 reading practice test | Killexams A2180-188 real questions |
How a lot 156-915-1 exam and prep manual cost?
Passing the 156-915-1 examination become quite tough for me until i used to be added with the question & answer by way of killexams. some of the topics regarded very tough to me. attempted plenty to examine the books, however failed as time turned into brief. in the end, the sell off helped me understand the topics and wrap up my guidance in 10 days time. excellent manual, killexams. My heartfelt thanks to you.
these 156-915-1 real test questions works within the actual test.
i have advised about your gadgets to numerous partners and companions, and theyre all extraordinarily fulfilled. a great deal obliged killexams.com Questions & solutions for boosting up my career and helping me plan nicely for my excessiveexams. a whole lot preferred over again. I need to say that i am your greatest fan! I want you to recognize that I cleared my 156-915-1 exam these days, deliberating the 156-915-1 route notes i purchased from you. I solved 86/95 questions within theexam. you are the quality training company.
I simply experienced 156-915-1 examination questions, there's not anything like this.
We need to learn how to pick our thoughts simply the equal manner, we pick out our garments everyday. that is the power we can habitat.Having said that If we need to do matters in our life, we must battle difficult to understand all its powers. I did so and labored hard on killexams.com to find out terrific function in 156-915-1 exam with the assist of killexams.com that proved very active and top notch program to find out favored role in 156-915-1 examination.It turned into a really perfect application to make my life relaxed.
Little effor, massive output, terrific Questions/answers.
killexams.Com Q&A is the most nice way i have ever lengthy beyond over to get geared up and skip IT checks. I desiremore people thought approximately it. But then, there is probably greater risks someone must close it down. The element is, it provides for the same problem what I should apprehend for an examination. Whats more I mean various IT assessments, 156-915-1 with 88% marks. My companion utilized killexams.Com Q&A for lots special certificates, all terrific and big. In reality stable, my individual top alternatives.
Is there a way to pass 156-915-1 exam at first attempt?
Despite having a full-time job along with family responsibilities, I decided to sit for the 156-915-1 exam. And I was in search of simple, short and strategic guideline to utilize 12 days time before exam. I got all these in killexams.com Q&A. It contained concise answers that were easy to remember. Thanks a lot.
surprised to peer 156-915-1 ultra-cutting-edge dumps!
killexams.com works! I passed this exam very last fall and at that point over 90% of the questions had been in realitylegitimate. Theyll be rather likely to nonetheless be legitimate as killexams.com cares to replace their substances regularly. killexams.com is a great enterprise which has helped me greater than once. Im a regular, so hoping for cut price for my next package deal!
That was Awesome! I got real exam questions of 156-915-1 exam.
Killexams.Com is a remarkable internet website online for 156-915-1 certification material. While i discovered you at the internet, I practicallyjoyed in excitement as it have become exactly what i used to be searching out. I used to be searching out some real and plenty much less high-priced help on line because I didnt have the time to undergo bunch of books. I found enough look at question herethat proved to be very useful. I used for you to score nicely in my CheckPoint test and Im obliged.
worked difficult on 156-915-1 books, but the whole thing changed into in the Q&A.
I am 156-915-1 certified now, way to this killexams.Com internet site. Theyve got a wonderful series of thoughts dumps and examination guidance sources, I significantly utilized them for my 156-915-1 certification remaining one year, and this time their sftuff is just as suitable. The questions are genuine, and the trying out engine works notable. No troubles detected. I definitely ordered it, practiced for a week or so, then went in and surpassed the 156-915-1 examination. Thats what the perfectexam schooling need to be like for everybody, I advocate killexams.
wherein have to I seek to get 156-915-1 actual take a look at questions?
I recognize the struggles made in growing the examination simulator. its far superb. i exceeded my 156-915-1 exam especially with questions and answers supplied with the aid of killexams.com crew
were given no trouble! 3 days instruction of 156-915-1 actual test questions is required.
Killexams.Com questions and answers helped me to recognize what precisely is predicted in the exam 156-915-1. I organized properly inside 10 days of instruction and finished all of the questions of exam in 80 mins. It incorporate the subjects similar to examination factor of view and makes you memorize all of the topics without difficulty and correctly. It also helped me to recognize a way to control the time to complete the examination before time. It is best method.
Killexams HP0-601 real questions | Killexams 050-694 test questions | Killexams Maya12-A dump | Killexams HP0-J38 practice questions | Killexams 310-813 test prep | Killexams HP2-E60 Practice test | Killexams 9A0-086 study guide | Killexams FM0-302 entrance exam | Killexams VCP510PSE test answers | Killexams C9560-023 exam cram | Killexams HP2-Z31 mock test | Killexams HP0-095 practice exam | Killexams HP2-N51 cbt | Killexams EK0-001 Practice Test | Killexams CVA sample test | Killexams JN0-533 study tools | Killexams C90-06A free test | Killexams 7303-1 real questions | Killexams HP0-083 test questions | Killexams BCCPP practice questions |
3COM [8 Certification Exam(s) ]
AccessData [1 Certification Exam(s) ]
ACFE [1 Certification Exam(s) ]
ACI [3 Certification Exam(s) ]
Acme-Packet [1 Certification Exam(s) ]
ACSM [4 Certification Exam(s) ]
ACT [1 Certification Exam(s) ]
Admission-Tests [12 Certification Exam(s) ]
ADOBE [92 Certification Exam(s) ]
AFP [1 Certification Exam(s) ]
AICPA [2 Certification Exam(s) ]
AIIM [1 Certification Exam(s) ]
Alcatel-Lucent [13 Certification Exam(s) ]
Alfresco [1 Certification Exam(s) ]
Altiris [3 Certification Exam(s) ]
Amazon [2 Certification Exam(s) ]
American-College [2 Certification Exam(s) ]
Android [4 Certification Exam(s) ]
APA [1 Certification Exam(s) ]
APC [2 Certification Exam(s) ]
APICS [2 Certification Exam(s) ]
Apple [69 Certification Exam(s) ]
AppSense [1 Certification Exam(s) ]
APTUSC [1 Certification Exam(s) ]
Arizona-Education [1 Certification Exam(s) ]
ARM [1 Certification Exam(s) ]
Aruba [6 Certification Exam(s) ]
ASIS [2 Certification Exam(s) ]
ASQ [3 Certification Exam(s) ]
ASTQB [8 Certification Exam(s) ]
Autodesk [2 Certification Exam(s) ]
Avaya [95 Certification Exam(s) ]
Axis [1 Certification Exam(s) ]
Banking [1 Certification Exam(s) ]
BEA [5 Certification Exam(s) ]
BICSI [2 Certification Exam(s) ]
BlackBerry [17 Certification Exam(s) ]
BlueCoat [2 Certification Exam(s) ]
Brocade [4 Certification Exam(s) ]
Business-Objects [11 Certification Exam(s) ]
Business-Tests [4 Certification Exam(s) ]
CA-Technologies [21 Certification Exam(s) ]
Certification-Board [10 Certification Exam(s) ]
Certiport [3 Certification Exam(s) ]
CheckPoint [40 Certification Exam(s) ]
CIPS [4 Certification Exam(s) ]
Cisco [315 Certification Exam(s) ]
Citrix [46 Certification Exam(s) ]
CIW [17 Certification Exam(s) ]
Cloudera [10 Certification Exam(s) ]
Cognos [19 Certification Exam(s) ]
College-Board [2 Certification Exam(s) ]
CompTIA [74 Certification Exam(s) ]
ComputerAssociates [6 Certification Exam(s) ]
CPP-Institute [1 Certification Exam(s) ]
CSP [1 Certification Exam(s) ]
CWNA [1 Certification Exam(s) ]
CWNP [13 Certification Exam(s) ]
Dassault [2 Certification Exam(s) ]
DELL [9 Certification Exam(s) ]
DMI [1 Certification Exam(s) ]
ECCouncil [21 Certification Exam(s) ]
ECDL [1 Certification Exam(s) ]
EMC [127 Certification Exam(s) ]
Enterasys [13 Certification Exam(s) ]
Ericsson [5 Certification Exam(s) ]
Esri [2 Certification Exam(s) ]
ExamExpress [15 Certification Exam(s) ]
Exin [40 Certification Exam(s) ]
ExtremeNetworks [3 Certification Exam(s) ]
F5-Networks [20 Certification Exam(s) ]
FCTC [2 Certification Exam(s) ]
Filemaker [9 Certification Exam(s) ]
Financial [36 Certification Exam(s) ]
Fortinet [12 Certification Exam(s) ]
Foundry [6 Certification Exam(s) ]
Fujitsu [2 Certification Exam(s) ]
GAQM [8 Certification Exam(s) ]
Genesys [4 Certification Exam(s) ]
GIAC [15 Certification Exam(s) ]
Google [4 Certification Exam(s) ]
GuidanceSoftware [2 Certification Exam(s) ]
H3C [1 Certification Exam(s) ]
HDI [9 Certification Exam(s) ]
Healthcare [3 Certification Exam(s) ]
HIPAA [2 Certification Exam(s) ]
Hitachi [28 Certification Exam(s) ]
Hortonworks [4 Certification Exam(s) ]
Hospitality [2 Certification Exam(s) ]
HP [744 Certification Exam(s) ]
HR [2 Certification Exam(s) ]
HRCI [1 Certification Exam(s) ]
Huawei [21 Certification Exam(s) ]
Hyperion [10 Certification Exam(s) ]
IAAP [1 Certification Exam(s) ]
IBM [1520 Certification Exam(s) ]
IBQH [1 Certification Exam(s) ]
ICAI [1 Certification Exam(s) ]
ICDL [6 Certification Exam(s) ]
IEEE [1 Certification Exam(s) ]
IELTS [1 Certification Exam(s) ]
IFPUG [1 Certification Exam(s) ]
IIA [3 Certification Exam(s) ]
IIBA [2 Certification Exam(s) ]
IISFA [1 Certification Exam(s) ]
Intel [2 Certification Exam(s) ]
IQN [1 Certification Exam(s) ]
IRS [1 Certification Exam(s) ]
ISA [1 Certification Exam(s) ]
ISACA [4 Certification Exam(s) ]
ISC2 [6 Certification Exam(s) ]
ISEB [24 Certification Exam(s) ]
Isilon [4 Certification Exam(s) ]
ISM [6 Certification Exam(s) ]
iSQI [7 Certification Exam(s) ]
ITEC [1 Certification Exam(s) ]
Juniper [63 Certification Exam(s) ]
Legato [5 Certification Exam(s) ]
Liferay [1 Certification Exam(s) ]
Lotus [66 Certification Exam(s) ]
LPI [23 Certification Exam(s) ]
LSI [3 Certification Exam(s) ]
Magento [3 Certification Exam(s) ]
Maintenance [2 Certification Exam(s) ]
McAfee [8 Certification Exam(s) ]
McData [3 Certification Exam(s) ]
Medical [25 Certification Exam(s) ]
Microsoft [362 Certification Exam(s) ]
Mile2 [2 Certification Exam(s) ]
Military [1 Certification Exam(s) ]
Misc [1 Certification Exam(s) ]
Motorola [7 Certification Exam(s) ]
mySQL [4 Certification Exam(s) ]
NCLEX [2 Certification Exam(s) ]
Network-General [12 Certification Exam(s) ]
NetworkAppliance [36 Certification Exam(s) ]
NI [1 Certification Exam(s) ]
NIELIT [1 Certification Exam(s) ]
Nokia [6 Certification Exam(s) ]
Nortel [130 Certification Exam(s) ]
Novell [37 Certification Exam(s) ]
OMG [10 Certification Exam(s) ]
Oracle [262 Certification Exam(s) ]
P&C [1 Certification Exam(s) ]
Palo-Alto [4 Certification Exam(s) ]
PARCC [1 Certification Exam(s) ]
PayPal [1 Certification Exam(s) ]
Pegasystems [11 Certification Exam(s) ]
PEOPLECERT [4 Certification Exam(s) ]
PMI [15 Certification Exam(s) ]
Polycom [2 Certification Exam(s) ]
PostgreSQL-CE [1 Certification Exam(s) ]
Prince2 [6 Certification Exam(s) ]
PRMIA [1 Certification Exam(s) ]
PsychCorp [1 Certification Exam(s) ]
PTCB [2 Certification Exam(s) ]
QAI [1 Certification Exam(s) ]
QlikView [1 Certification Exam(s) ]
Quality-Assurance [7 Certification Exam(s) ]
RACC [1 Certification Exam(s) ]
Real-Estate [1 Certification Exam(s) ]
RedHat [8 Certification Exam(s) ]
RES [5 Certification Exam(s) ]
Riverbed [8 Certification Exam(s) ]
RSA [15 Certification Exam(s) ]
Sair [8 Certification Exam(s) ]
Salesforce [5 Certification Exam(s) ]
SANS [1 Certification Exam(s) ]
SAP [98 Certification Exam(s) ]
SASInstitute [15 Certification Exam(s) ]
SAT [1 Certification Exam(s) ]
SCO [10 Certification Exam(s) ]
SCP [6 Certification Exam(s) ]
SDI [3 Certification Exam(s) ]
See-Beyond [1 Certification Exam(s) ]
Siemens [1 Certification Exam(s) ]
Snia [7 Certification Exam(s) ]
SOA [15 Certification Exam(s) ]
Social-Work-Board [1 Certification Exam(s) ]
SpringSource [1 Certification Exam(s) ]
SUN [63 Certification Exam(s) ]
SUSE [1 Certification Exam(s) ]
Sybase [17 Certification Exam(s) ]
Symantec [133 Certification Exam(s) ]
Teacher-Certification [4 Certification Exam(s) ]
The-Open-Group [8 Certification Exam(s) ]
TIA [3 Certification Exam(s) ]
Tibco [18 Certification Exam(s) ]
Trend [1 Certification Exam(s) ]
TruSecure [1 Certification Exam(s) ]
USMLE [1 Certification Exam(s) ]
VCE [6 Certification Exam(s) ]
Veeam [2 Certification Exam(s) ]
Veritas [32 Certification Exam(s) ]
Vmware [57 Certification Exam(s) ]
Wonderlic [1 Certification Exam(s) ]
Worldatwork [2 Certification Exam(s) ]
XML-Master [3 Certification Exam(s) ]
Zend [6 Certification Exam(s) ]
Dropmark : http://killexams.dropmark.com/367904/11794948
Wordpress : http://wp.me/p7SJ6L-1Hz
Dropmark-Text : http://killexams.dropmark.com/367904/12566091
Blogspot : http://killexamsbraindump.blogspot.com/2017/12/pass4sure-156-915-1-practice-tests-with.html
RSS Feed : http://feeds.feedburner.com/JustStudyTheseCheckpoint156-915-1QuestionsAndPassTheRealTest
Box.net : https://app.box.com/s/4o35bpki0l4wj948ykfa7jb167f77jss